Norges Bank
XFOR icon

Norges Bank’s X4 Pharmaceuticals XFOR Stock Holding History

Norges Bank’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-923
Closed -$48.5K – 2178
2022
Q1 		$48.5K Hold
923
– – ﹤0.01% 2161
2021
Q4 		$63K Hold
923
– – ﹤0.01% 2202
2021
Q3 		$147K Buy
+923
New +$152K ﹤0.01% 2266

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
TLP
Tri Locum Partners New York $713M AUM 68.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

Norges Bank's XFOR Position: Q2 2022 in Review

Norges Bank sold out of X4 Pharmaceuticals (XFOR) in Q2 2022, closing a stake of 923 shares — an estimated $48.5K sold.

Norges Bank first reported a position in XFOR in Q3 2021 and held it in 3 quarters. The position peaked at $147K in Q3 2021. 49 funds tracked by Wall St. Rank hold XFOR as of Q2 2022.

  • Norges Bank reported no remaining X4 Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Norges Bank sold 923 X4 Pharmaceuticals shares in Q2 2022, an estimated $48.5K.
  • Norges Bank first reported a position in X4 Pharmaceuticals in Q3 2021 and held it in 3 quarters.
  • Norges Bank's X4 Pharmaceuticals position peaked at $147K in Q3 2021.
  • 49 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2022.

Based on Norges Bank's 13F filing for Q2 2022, filed 11 Aug 2022.